{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:53:48Z","timestamp":1790610828868,"version":"4.1.0"},"reference-count":95,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the clonal proliferation of myeloid precursors and rapid progression. Historically consisting of intensive chemotherapy, AML management has evolved significantly due to advances in molecular diagnostics and risk stratification. This review discusses current therapeutic paradigms in AML, emphasizing the growing role of personalized medicine across age and risk groups. For younger, fit patients, intensive regimens such as the \u201c7 + 3\u201d protocol remain the standard, often enhanced by targeted agents like FMS-like tyrosine kinase 3 (FLT3) and IDH inhibitors. Older or unfit individuals benefit from low-intensity treatments such as hypomethylating agents combined with venetoclax, now considered a frontline standard of care. The use of liposomal chemotherapy (CPX-351), measurable residual disease (MRD) monitoring, and maintenance therapy further refine post-remission strategies. Emerging therapies, including menin inhibitors, antibody\u2013drug conjugates, and immunotherapies like CAR-T cells and vaccines, offer additional options, especially in relapsed\/refractory settings. This comprehensive review outlines the current landscape and future directions in AML therapy, emphasizing the transition toward individualized, mutation-driven treatment strategies.<\/jats:p>","DOI":"10.3390\/cancers17172824","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:01:01Z","timestamp":1756454461000},"page":"2824","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evolving Paradigms in Acute Myeloid Leukemia: Personalized Approaches to Therapy Across Age and Risk Groups"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-1408","authenticated-orcid":false,"given":"Sumeet K.","family":"Yadav","sequence":"first","affiliation":[{"name":"Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN 56001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-5846","authenticated-orcid":false,"given":"Utsav","family":"Joshi","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Fellowship Program, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guleid","family":"Hussein","sequence":"additional","affiliation":[{"name":"Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN 56001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Warsame","sequence":"additional","affiliation":[{"name":"Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN 56001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8508-9371","authenticated-orcid":false,"given":"Bolun","family":"Liu","sequence":"additional","affiliation":[{"name":"Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN 56001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9960-5581","authenticated-orcid":false,"given":"Abhash","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Kathmandu Medical College, Kathmandu University, Kathmandu 44600, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Krastev","sequence":"additional","affiliation":[{"name":"College of Medicine, Kansas City University, Kansas, MO 64106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hariprasad Reddy","family":"Korsapati","sequence":"additional","affiliation":[{"name":"Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN 56001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrit","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mayo Clinic Health System, Mankato, MN 56001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of Acute Myeloid Leukemia Diagnosis and Pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/CCO.0000000000000965","article-title":"Recent advances in precision medicine for acute myeloid leukemia","volume":"35","author":"Bullinger","year":"2023","journal-title":"Curr. Opin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.3324\/haematol.2020.269134","article-title":"Dose intensity for induction in acute myeloid leukemia: What, when, and for whom?","volume":"106","author":"McCurdy","year":"2021","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Aydin, S., Passera, R., Cerrano, M., Giai, V., D\u2019Ardia, S., Iovino, G., Dellacasa, C.M., Audisio, E., and Busca, A. (2023). Combining the HCT-CI, G8, and AML-Score for Fitness Evaluation of Elderly Patients with Acute Myeloid Leukemia: A Single Center Analysis. Cancers, 15.","DOI":"10.3390\/cancers15041002"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: A project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"key":"ref_19","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.2004.05285.x","article-title":"Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies","volume":"128","author":"Boogaerts","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline Dose Intensification in Acute Myeloid Leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: Results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/sj.leu.2404313","article-title":"The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia","volume":"20","author":"Buccisano","year":"2006","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/cncr.24373","article-title":"Outcomes and quality of care in acute myeloid leukemia over 40 years","volume":"115","author":"Alibhai","year":"2009","journal-title":"Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8885","DOI":"10.1038\/s41598-022-12813-1","article-title":"High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia","volume":"12","author":"Senjo","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2021013671","article-title":"Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML","volume":"139","author":"Min","year":"2022","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","article-title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: Long-term analysis of a phase II randomized trial","volume":"100","author":"Heuser","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.2018.208637","article-title":"Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia","volume":"105","author":"Talati","year":"2020","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00277-023-05109-5","article-title":"Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: Retrospective analysis of an electronic medical record database in the United States","volume":"102","author":"Zeidan","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.27510","article-title":"Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries","volume":"100","author":"Dumas","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/hematology.2021000257","article-title":"Allogeneic hematopoietic cell transplantation for older patients","volume":"2021","author":"Lin","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41409-023-02027-y","article-title":"Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"58","author":"Maffini","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7 + 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-022-01361-w","article-title":"Efficacy and safety of CPX-351 versus 7\u2009 + \u20093 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk\/secondary AML: Post hoc analysis of a randomized, phase 3 trial","volume":"15","author":"Cortes","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/bloodadvances.2024014900","article-title":"Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)","volume":"9","author":"Chua","year":"2025","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/bloodadvances.2022008282","article-title":"Characteristics and prognostic impact of IDH mutations in AML: A COG, SWOG, and ECOG analysis","volume":"7","author":"Alonzo","year":"2023","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"Fenaux","year":"2023","journal-title":"Blood Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: A randomized phase 3 trial","volume":"141","author":"Montesinos","year":"2023","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Niu, J., Peng, D., and Liu, L. (2022). Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.896426"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41419-023-06075-6","article-title":"Bcl-2 inhibition combined with PPAR\u03b1 activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia","volume":"14","author":"Xie","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/2159-8290.CD-16-0921","article-title":"BCL2 Inhibition by Venetoclax: Targeting the Achilles\u2019 Heel of the Acute Myeloid Leukemia Stem Cell?","volume":"6","author":"Pullarkat","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2022-158518","article-title":"Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy","volume":"140","author":"Pratz","year":"2022","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2024-207842","article-title":"Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia","volume":"144","author":"Marconi","year":"2024","journal-title":"Blood"},{"key":"ref_60","first-page":"1682","article-title":"Disruption of the menin-MLL interaction triggers menin protein degradation via ubiquitin-proteasome pathway","volume":"9","author":"Wu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1007\/s00432-023-04752-9","article-title":"Targeting the undruggable: Menin inhibitors ante portas","volume":"149","author":"Dempke","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine\/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1182\/blood-2023-182026","article-title":"Synergistic Growth Inhibition of NPM1 Mutant AML PDX By Combined Therapy with BCL-2 Inhibitor Venetoclax (ABT-199) and Menin Inhibitor DS-1594b In Vivo","volume":"142","author":"Ciaurro","year":"2023","journal-title":"Blood"},{"key":"ref_66","unstructured":"Borate, U.M. (2025, May 10). Safety and Efficacy of Dual Menin and FLT3 Inhibition in Patients With Relapsed\/Refractory FLT3- Mutated Acute Myeloid Leukemia Containing a Concurrent MLL-Rearrangement or NPM1 Mutation: A Phase I (Ph I) Study of SNDX-5613 + Gilteritinib. Available online: https:\/\/cancer.osu.edu\/for-patients-and-caregivers\/learn-about-cancers-and-treatments\/innovation-at-the-james\/clinical-trials\/find-a-clinical-trial\/safety-and-efficacy-of-dual-menin-and-flt3."},{"key":"ref_67","first-page":"2289","article-title":"Maintenance therapy in acute myeloid leukemia: Advances and controversies","volume":"108","author":"Senapati","year":"2023","journal-title":"Haematologica"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-013-1940-9","article-title":"Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)","volume":"93","author":"Tawfik","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjh.16433","article-title":"Allogeneic stem cell transplantation in AML with t (6; 9) (p23; q34); DEK-NUP214 shows a favourable outcome when performed in first complete remission","volume":"189","author":"Labopin","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.bbmt.2020.06.007","article-title":"Recent Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia","volume":"26","author":"Bittencourt","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","article-title":"Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia","volume":"29","author":"Fathi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Samra, B., Konopleva, M., Isidori, A., Daver, N., and DiNardo, C. (2020). Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.562558"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/hematolrep16020024","article-title":"A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia","volume":"16","author":"Candoni","year":"2024","journal-title":"Hematol. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular Minimal Residual Disease in Acute Myeloid Leukemia","volume":"378","author":"Grob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Moritz, J., Schwab, A., Reinisch, A., Zebisch, A., Sill, H., and W\u00f6lfler, A. (2024). Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030599"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/PPO.0000000000000635","article-title":"Antibody-Drug Conjugates in Myeloid Leukemias","volume":"28","author":"Senapati","year":"2022","journal-title":"Cancer J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1158\/1078-0432.CCR-20-2149","article-title":"Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia","volume":"27","author":"Han","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1535-7163.MCT-17-0742","article-title":"Characterization of SGN-CD123A, A Potent CD123-Directed Antibody\u2013Drug Conjugate for Acute Myeloid Leukemia","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1158\/1535-7163.MCT-20-0407","article-title":"LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia","volume":"19","author":"Anami","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/1078-0432.CCR-18-0333","article-title":"An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia","volume":"25","author":"Zheng","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41375-025-02528-3","article-title":"Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed\/refractory acute myeloid leukemia","volume":"39","author":"Abedin","year":"2025","journal-title":"Leukemia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2019-128648","article-title":"Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/PPO.0000000000000573","article-title":"Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia","volume":"28","author":"Haddad","year":"2022","journal-title":"Cancer J."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Tabata, R., Chi, S., Yuda, J., and Minami, Y. (2021). Emerging Immunotherapy for Acute Myeloid Leukemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041944"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Liao, D., Wang, M., Liao, Y., Li, J., and Niu, T. (2019). A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00609"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed\/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed\/Refractory Acute Myeloid Leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: The ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","article-title":"Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: A phase 1a dose-escalation study","volume":"65","author":"Ravandi","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Barbullushi, K., Rampi, N., Serpenti, F., Scium\u00e8, M., Fabris, S., De Roberto, P., and Fracchiolla, N.S. (2022). Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?. Cancers, 14.","DOI":"10.3390\/cancers14122994"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jcyt.2024.02.009","article-title":"Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: A systematic review","volume":"26","author":"Alizadeh","year":"2024","journal-title":"Cytotherapy"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2824\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:34:55Z","timestamp":1760034895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":95,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17172824"],"URL":"https:\/\/doi.org\/10.3390\/cancers17172824","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}